University of California, Los Angeles

Running trials

• Recruiting

  IMAGES: Identifying Metabolic Imaging Association With Genicular Artery Embolization Success

  NCT07494838· Lucas R. Cusumano, MD· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Effects of nVNS on Stress Reactivity in IBS

  NCT07926945· University of California, Los Angeles· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Recruiting

  C-Carbs: A CGM-guided Approach to Teaching Carb Awareness

  NCT07807280· University of California, Los Angeles· Source

• Recruiting

  Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial

  NCT07168395· University of California, Los Angeles· Source

• Recruiting

  Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis

  NCT07756567· University of California, San Diego· Source

• Not yet recruiting

  Signatera Assessment in Early-Stage Endometrial Cancer

  NCT07339384· Natera, Inc.· Source

• Not yet recruiting

  Screening For Social Determinants Of Health In Routine Diabetes Care

  NCT07706803· University of California, Los Angeles· Source

• Not yet recruiting

  Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

  NCT07681713· Phase 3· PTC Therapeutics· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· Phase 3· Duke University· Source

• Recruiting

  Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

  NCT07529808· Phase 1/2· BigHat Biosciences, Inc.· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

  NCT07613398· Matthias Stuber· Source

• Not yet recruiting

  Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension

  NCT07605468· Stanford University· Source

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  NCT07297979· Phase 1· Amgen· Source

• Recruiting

  A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

  NCT07584226· Phase 1/2· Relay Therapeutics, Inc.· Source

• Recruiting

  Sleep Learning Education and Empowerment for Older Korean Immigrants

  NCT07387406· University of California, Los Angeles· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

  NCT06875128· Phase 2· Delcath Systems Inc.· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

  NCT07293585· Phase 3· Jonsson Comprehensive Cancer Center· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Active, not recruiting

  Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

  NCT07287189· Phase 2· Satellos Bioscience, Inc.· Source

• Recruiting

  Automated Insulin for Management of Intrapartum Glycemia

  NCT06883344· University of California, San Francisco· Source

• Recruiting

  Clinical Outcomes and Major Adverse Events in Patients Treated With Physician-Modified Fenestrated and Branched Stent Grafts

  NCT06526676· University of California, Los Angeles· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Inter-Brain Synchrony in Schizophrenia

  NCT07177261· University of California, Los Angeles· Source

• Recruiting

  Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults

  NCT06444360· Westat· Source

• Enrolling by invitation

  Understanding Freezing of Gait Using Brain Signals and Virtual Reality

  NCT07092995· University of California, Los Angeles· Source

• Recruiting

  New T-UP: Engaging Vulnerable Students in Diabetes Prevention

  NCT07225218· University of California, Los Angeles· Source

• Recruiting

  Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

  NCT07449039· University of California, Los Angeles· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  Telerehabilitation In The Home After Stroke

  NCT06682429· University of California, Los Angeles· Source

• Recruiting

  Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

  NCT04774536· Phase 1/2· Mark Walters, MD· Source

• Enrolling by invitation

  An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

  NCT06867107· Phase 2· Satellos Bioscience, Inc.· Source

• Active, not recruiting

  PSMA PET Combined With MRI for the Detection of PCa

  NCT07052214· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

  NCT07136623· Eko Devices, Inc.· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Amgen· Source

• Recruiting

  Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

  NCT07077239· Jonsson Comprehensive Cancer Center· Source

• Recruiting

  XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

  NCT06895070· XVIVO Perfusion· Source

• Active, not recruiting

  TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

  NCT07287800· Phase 1/2· University of California, Los Angeles· Source

• Recruiting

  PiMZ Longitudinal Cohort (PiMZ Logic)

  NCT06505603· Columbia University· Source

• Recruiting

  Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

  NCT06517641· Phase 2· Medical College of Wisconsin· Source

Showing 50 of 214.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer8 recruiting
• Childhood cancers7 recruiting
• Parkinson disease7 recruiting
• Colorectal cancer6 recruiting
• Lung cancer6 recruiting
• Alzheimer disease5 recruiting
• Pancreatic cancer5 recruiting
• Gastric and oesophageal cancer4 recruiting
• Glioblastoma4 recruiting
• Head and neck cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Schizophrenia4 recruiting
• Type 2 diabetes4 recruiting
• Acute myeloid leukaemia3 recruiting
• COPD3 recruiting
• Endometrial cancer3 recruiting
• Epilepsy3 recruiting
• Melanoma3 recruiting
• Stroke3 recruiting
• Type 1 diabetes3 recruiting
• ALS (motor neurone disease)2 recruiting
• Autism2 recruiting
• Bladder cancer2 recruiting
• Congenital heart disease2 recruiting
• Cystic fibrosis2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Frontotemporal dementia2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Irritable bowel syndrome2 recruiting
• Lewy body dementia2 recruiting
• Lupus (SLE)2 recruiting
• Multiple system atrophy2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroendocrine tumours2 recruiting
• Osteoarthritis2 recruiting
• Ovarian cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sarcoma2 recruiting
• Sickle cell disease2 recruiting
• Spinal cord injury2 recruiting
• Vascular dementia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Aplastic anaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Barrett's oesophagus1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometriosis1 recruiting
• Fabry disease1 recruiting
• Friedreich ataxia1 recruiting
• HIV1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Insomnia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myocarditis1 recruiting
• Peripheral artery disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Terminated

  Open-Label Extension Study to Pioneer Study 6058-SCD-101

  NCT07401823· Phase 2· Fulcrum Therapeutics· Source

• Recruiting

  Suvorexant for Treatment of AUD and PTSD

  NCT06679062· Phase 2· Pharmacotherapies for Alcohol and Substance Use Disorders Alliance· Source

• Completed

  SMART Pilot Trial of Glycemic Screening Outreach

  NCT06915194· University of California, Los Angeles· Source

• Completed

  Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

  NCT06235814· University of California, Los Angeles· Source

• Withdrawn

  Pediatric Neural Sleeve Validation

  NCT05660096· University of California, Los Angeles· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study of INKmune in Patients With mCRPC (CaRe Prostate)

  NCT06056791· Phase 1/2· Inmune Bio, Inc.· Source

• Completed

  T-UP: Engaging Vulnerable Students in Diabetes Prevention

  NCT06385015· University of California, Los Angeles· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Terminated

  Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

  NCT05841706· Early phase 1· Jonsson Comprehensive Cancer Center· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

  NCT05908240· University of Pennsylvania· Source

• Completed

  A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

  NCT05899816· Phase 3· Amgen· Source

• Terminated

  Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

  NCT05814666· Phase 2· Flamingo Therapeutics NV· Source

• Completed

  Feasibility Trial of a Lifestyle Intervention for CHR-P

  NCT05532683· University of California, Los Angeles· Source

• Terminated

  Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care

  NCT05456139· Florida State University· Source

• Terminated

  A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  NCT05317078· Phase 1· Amgen· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Amgen· Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Phase 1· Day One Biopharmaceuticals, Inc.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

  NCT05568927· University of California, San Diego· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

  NCT05383872· InSightec· Source

• Completed

  Remote Assessment and Intervention for Behavior Problems in Kids With TSC

  NCT06311474· University of California, Los Angeles· Source

• Terminated

  Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

  NCT05130866· Phase 2/3· Recursion Pharmaceuticals Inc.· Source

• Completed

  LIFUP for Treatment of Motor Deficits in Parkinson's Disease

  NCT04593875· University of California, Los Angeles· Source

• Completed

  Luteolin for the Treatment of People With Schizophrenia

  NCT05204407· University of Maryland, Baltimore· Source

• Completed

  Daily Habits & Consumer Preferences Study

  NCT05402137· University of California, Los Angeles· Source

• Completed

  Metformin Treatment in Progressive Multiple Sclerosis

  NCT05349474· Early phase 1· University of California, Los Angeles· Source

• Completed

  A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

  NCT05293496· Phase 1· MacroGenics· Source

• Terminated

  A Study to Investigate LYL797 in Adults With Solid Tumors

  NCT05274451· Phase 1· Lyell Immunopharma, Inc.· Source

• Terminated

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· Phase 2· Tempus AI· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· ALX Oncology Inc.· Source

• Completed

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

  NCT05169580· Phase 1· Fulcrum Therapeutics· Source

• Completed

  Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

  NCT04919642· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Completed

  A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

  NCT04874350· Phase 2· Lipocine Inc.· Source

• Completed

  A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

  NCT05091346· Phase 1/2· Eisai Inc.· Source

• Completed

  Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

  NCT05041257· Phase 2· AbbVie· Source

• Completed

  A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

  NCT04853017· Phase 1· Elicio Therapeutics· Source

• Terminated

  KZR-261 in Subjects With Advanced Solid Malignancies

  NCT05047536· Phase 1· Kezar Life Sciences, Inc.· Source

• Completed

  Transcutaneous (Tragus) Vagal Nerve Stimulation for Post-op Afib

  NCT04514757· University of California, Los Angeles· Source

• Terminated

  Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

  NCT04506086· Phase 4· Amgen· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  Discrimination and the Brain-Gut-Microbiome (BGM) Axis

  NCT05120908· University of California, Los Angeles· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

  NCT04931823· Phase 1· Conjupro Biotherapeutics, Inc.· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Regeneron Pharmaceuticals· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· AbbVie· Source

Showing 50 of 98.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke400 works · 5 trials
• HIV376 works · 5 trials
• Obesity303 works · 4 trials
• Heart failure281 works · 4 trials
• Prostate cancer234 works · 25 trials
• Alzheimer disease218 works · 9 trials
• Lung cancer215 works · 31 trials
• Type 2 diabetes147 works · 6 trials
• Schizophrenia111 works · 10 trials
• Chronic kidney disease104 works · 4 trials
• Liver and biliary tract cancer101 works · 9 trials
• Epilepsy95 works · 6 trials
• Autism90 works · 5 trials
• Ovarian cancer90 works · 11 trials
• Colorectal cancer90 works · 16 trials
• Parkinson disease85 works · 11 trials
• Psoriasis83 works · 3 trials
• Melanoma83 works · 12 trials
• Coronary artery disease82 works · 5 trials
• Atrial fibrillation78 works · 2 trials
• Asthma73 works · 0 trials
• Glioblastoma66 works · 12 trials
• Depression63 works · 0 trials
• Macular degeneration58 works · 1 trial
• COPD58 works · 4 trials
• Glaucoma58 works · 0 trials
• Congenital heart disease56 works · 5 trials
• Atopic dermatitis (eczema)55 works · 5 trials
• Sarcoma54 works · 9 trials
• Pulmonary arterial hypertension53 works · 3 trials